Page 21 - AN-3-3

Advanced Neurology Alzheimer’s and Parkinson’s disease rodent models

4‐phenylbutyrate, a chemical chaperone. J Neurochem. 48. Takashiba S, Van Dyke TE, Amar S, Murayama Y, Soskolne
2007;101(6):1491-1504. AW, Shapira L. Differentiation of monocytes to macrophages
primes cells for lipopolysaccharide stimulation via
doi: 10.1111/j.1471-4159.2006.04440.x
accumulation of cytoplasmic nuclear factor kappaB. Infect
38. Miyazaki I, Isooka N, Wada K, Kikuoka R, Kitamura Y, Immun. 1999;67(11):5573-5578.
Asanuma M. Effects of enteric environmental modification
by coffee components on neurodegeneration in rotenone- doi: 10.1128/IAI.67.11.5573-5578.1999
treated mice. Cells. 2019;8(3):221. 49. Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson’s
doi: 10.3390/cells8030221 disease and its potential as therapeutic target. Transl
Neurodegener. 2015;4:19.
39. McQueen EG, Doyle AE, Smirk FH. Mechanism of
hypotensive action of reserpine, an alkaloid of Rauwolfia doi: 10.1186/s40035-015-0042-0
serpentina. Nature. 1954;174(4439):1015. 50. Herrera AJ, Castaño A, Venero JL, Cano J, Machado A.
doi: 10.1038/1741015b0 The single intranigral injection of LPS as a new model for
studying the selective effects of inflammatory reactions on
40. Leão AHFF, Sarmento-Silva AJ, Santos JR, Ribeiro AM, dopaminergic system. Neurobiol Dis. 2000;7(4):429-447.
Silva RH. Molecular, neurochemical, and behavioral
hallmarks of reserpine as a model for Parkinson’s disease: doi: 10.1006/nbdi.2000.0289
New perspectives to a long-standing model. Brain Pathol. 51. Iravani MM, Leung CCM, Sadeghian M, Haddon CO,
2015;25(4):377-390. Rose S, Jenner P. The acute and the long-term effects of
doi: 10.1111/bpa.12253 nigral lipopolysaccharide administration on dopaminergic
dysfunction and glial cell activation. Eur J Neurosci.
41. Rijntjes M, Meyer PT. No free lunch with herbal preparations: 2005;22(2):317-330.
Lessons from a case of parkinsonism and depression due
to herbal medicine containing reserpine. Front Neurol. doi: 10.1111/j.1460-9568.2005.04220.x
2019;10:634. 52. Qin L, Wu X, Block ML, et al. Systemic LPS causes chronic
doi: 10.3389/fneur.2019.00634 neuroinflammation and progressive neurodegeneration.
Glia. 2007;55(5):453-462.
42. Dey P, Kundu A, Kumar A, et al. Analysis of alkaloids (indole
alkaloids, isoquinoline alkaloids, tropane alkaloids). In: doi: 10.1002/glia.20467
Recent Advances in Natural Products Analysis. Netherlands: 53. Waku I, Magalhães MS, Alves CO, de Oliveira AR.
Elsevier; 2020. p. 505-567. Haloperidol-induced catalepsy as an animal model for
doi: 10.1016/B978-0-12-816455-6.00015-9 parkinsonism: A systematic review of experimental studies.
Eur J Neurosci. 2021;53(11):3743-3767.
43. Freis ED. Mental depression in hypertensive patients treated
for long periods with large doses of reserpine. N Engl J Med. doi: 10.1111/ejn.15222
1954;251(25):1006-1008. 54. Luthra PM, Barodia SK, Raghubir R. Antagonism of
doi: 10.1056/NEJM195412162512504 haloperidol-induced swim impairment in l-dopa and caffeine
treated mice: A pre-clinical model to study Parkinson’s
44. Steg G. Alpha-rigidity in reserpinized rats. Experientia. disease. J Neurosci Methods. 2009;178(2):284-290.
1964;20(2):79-80.
doi: 10.1016/j.jneumeth.2008.12.019
doi: 10.1007/BF02151251
55. Atack JR, Shook BC, Rassnick S, et al. JNJ-40255293, a novel
45. Carlsson M, Carlsson A. Marked locomotor stimulation adenosine A 2A/A 1 antagonist with efficacy in preclinical
in monoamine-depleted mice following treatment with models of Parkinson’s disease. ACS Chem Neurosci.
atropine in combination with clonidine. J Neural Transm 2014;5(10):1005-1019.
Park Dis Dement Sect. 1989;1(4):317-322.
doi: 10.1021/cn5001606
doi: 10.1007/BF02263486
56. Bollinger SR, Engers DW, Panarese JD, et al. Discovery,
46. Carlsson A, Lindqvist M, Magnusson T. structure-activity relationship, and biological
3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as characterization of a novel series of 6-((1 H -Pyrazolo ,3- b ]
[4
reserpine antagonists. Nature. 1957;180(4596):1200. pyridin-3-yl)amino)-benzo[ d ]isothiazole-3-carboxamides
doi: 10.1038/1801200a0 as positive allosteric modulators of the metabotropic
glutamate receptor 4. J Med Chem. 2019;62(1):342-358.
47. Duty S, Jenner P. Animal models of Parkinson’s disease:
A source of novel treatments and clues to the cause of the doi: 10.1021/acs.jmedchem.8b00994
disease. Br J Pharmacol. 2011;164(4):1357-1391.
57. Gasser T, Hardy J, Mizuno Y. Milestones in PD genetics.
doi: 10.1111/j.1476-5381.2011.01426.x Mov Disord. 2011;26(6):1042-1048.

Volume 3 Issue 3 (2024) 15 doi: 10.36922/an.2903